Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-03-0947.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-03-0947v1
101/9/3386    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsushima, T.
Right arrow Articles by Murakami, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsushima, T.
Right arrow Articles by Murakami, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted March 27, 2002
Accepted December 12, 2002

Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia

Takafumi Matsushima*, Hiroshi Handa, Akihiko Yokohama, Jun Nagasaki, Hiromi Koiso, Yoshitora Kin, Yoko Tanaka, Tohru Sakura, Norifumi Tsukamoto, Masamitsu Karasawa, Katsuhiko Itoh, Hisami Hirabayashi, Morio Sawamura, Shogo Shinonome, Shun-ichi Shimano, Shuichi Miyawaki, Yoshihisa Nojima, and Hirokazu Murakami

Third Department of Internal Medicine, Gunma University, Maebashi, Japan
Department of Internal Medicine, National Nishigunma Hospital, Shibukawa, Japan
Department of Internal Medicine, Fujioka General Hospital, Fujioka, Japan
Department of Internal Medicine, Fukaya Red Cross Hospital, Fukaya, Japan
Department of Internal Medicine, Gunma Cancer Center, Ohta, Japan
Division of Hematology, Saiseikai Maebashi Hospital, Maebashi, Japan
Division of Blood Transfusion Service, Gunma University Hospital, Maebashi, Japan
Department of Internal Medicine, National Takasaki Hospital, Takasaki, Japan
School of Health Sciences, Faculty of Medicine, Gunma University, Maebashi, Japan

* Corresponding author; email: tmatsu{at}showa.gunma-u.ac.jp.

By retrospectively analyzing 288 patients with de novo myelodysplastic syndrome (MDS), we sought to determine the prevalence and clinical characteristics of bone marrow eosinophilia and basophilia that were detected at presentation. Bone marrow eosinophilia and basophilia were defined as a differential count of each cell type exceeding 5.0% and 1.0%, respectively. Thirty-six out of 288 MDS patients (12.8%) fulfilled this criterion for bone marrow eosinophilia (MDS-Eos). Thirty-four patients (11.8%) showed basophilia (MDS-Bas), and 11 (3.8%) satisfied both criteria (MDS-EosBas). The remaining 229 patients had neither eosinophilia nor basophilia in their bone marrow (MDS-/-) at presentation. Cytogenetic analysis was carried out on unstimulated bone marrow cells obtained from 264 patients. When the cytogenetic categorization of the IPSS (International Prognostic Scoring System) for MDS was applied, significantly higher numbers of MDS-Eos and MDS-Bas patients had chromosomal abnormalities carrying intermediate or poor prognosis, compared with the MDS-/- patients. Specific chromosomal abnormalities and complex karyotypes were associated with MDS-Eos and/or MDS-Bas. In accordance with these results, the overall survival rate was significantly lower and the evolution to acute myelogenous leukemia (AML) occurred more frequently in the MDS-Eos and MDS-Bas than the MDS-/- patients. Multivariate analysis demonstrated that bone marrow basophilia was an independent risk factor for evolution to AML. Our study indicates that bone marrow eosinophilia and basophilia in MDS patients predict a poorer prognosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. Matsuda, U. Germing, I. Jinnai, M. Misumi, A. Kuendgen, S. Knipp, M. Aivado, M. Iwanaga, Y. Miyazaki, H. Tsushima, et al.
Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes
Blood, October 15, 2005; 106(8): 2633 - 2640.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020